Search research articles
Contact Us
Filters
Showing results (151-160 of 217) with videos related to
Page
of 22
Sort By:
Targeted Oncology
|
January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Nicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer Cell
|
October 22, 2011
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis
Nu Zhang, Ping Wei, Aihua Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2015
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Sun-Jin Kim, Ho Jeong Lee, Mark Seungwook Kim, et al.
Oncology
|
December 6, 2003
Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
Vinay K Puduvalli, Masood Hashmi, Leslie D McAllister, et al.
Cancer
|
November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma
Pierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Neuro-Oncology
|
May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Jeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Shaofang Wu, Feng Gao, Siyuan Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
Monica E Loghin, Michael D Prados, Patrick Wen, et al.
Neuro-Oncology
|
February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
Michael D Prados, W K Alfred Yung, Howard A Fine, et al.
Journal of Neuro-Oncology
|
July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 217) with videos related to
Sort By:
Page
of 22
Targeted Oncology
|
January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept
Nicole Shonka, Yuji Piao, Mark Gilbert, et al.
Cancer Cell
|
October 22, 2011
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis
Nu Zhang, Ping Wei, Aihua Gong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2015
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Sun-Jin Kim, Ho Jeong Lee, Mark Seungwook Kim, et al.
Oncology
|
December 6, 2003
Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
Vinay K Puduvalli, Masood Hashmi, Leslie D McAllister, et al.
Cancer
|
November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma
Pierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Neuro-Oncology
|
May 12, 2011
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Jeffrey S Wefel, Timothy Cloughesy, James L Zazzali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2019
<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Shaofang Wu, Feng Gao, Siyuan Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
Monica E Loghin, Michael D Prados, Patrick Wen, et al.
Neuro-Oncology
|
February 11, 2004
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
Michael D Prados, W K Alfred Yung, Howard A Fine, et al.
Journal of Neuro-Oncology
|
July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Page
of 22